Companion Society Meetings
International Society of Urological Pathology
The Importance of Pathologic Evaluation in Active Surveillance of Genitourinary Tumors
Saturday, March 17, 2018, 7:00 - 10:00 PM
3 CME and 3 SAMs
Steven Shen, MD, PhD, Houston Methodist Hospital, Houston, TX
Michelle Hirsch, MD, PhD, Brigham and Women's Hospital, Boston, MA
There is a trend to treat low grade, low stage carcinomas of the genitourinary tract more conservatively as they have been shown to be associated with a favorable outcome in many cases. However, it is important for pathologists to be able to distinguish such low grade lesions from those that may be more aggressive, and to understand the clinical consequences. The 2018 ISUP Companion Meeting will be addressing active surveillance and management of such low grade, low stage carcinomas in the prostate, kidney and bladder. The session will begin with a clinical overview of active surveillance/minimal management of genitourinary tract cancers. This guest lecture will be given by Dr. Alan So, who is a Uro-oncologist in the Department of Urological Sciences at the University of British Columbia. Dr. So's lecture will then be followed by three expert pathologists who will be addressing the importance of how pathologic diagnoses affect active surveillance decision making in three main GU organs, i.e. the prostate, kidney, and bladder. The session will conclude with panel discussion using case examples with audience participation.
Upon completion of this educational activity, the learner will be able to:
- Understand the definition, indications and risk stratification of active surveillance in the treatment of genitourinary cancers
- Understand the importance and relevance of pathologic diagnoses in active surveillance
- Understand the histologic interpretation and reporting of pathologic parameters in biopsy specimens from prostate, kidney and bladder cancers
- Recognize the value of ancillary studies and it's limitation in the biopsy diagnosis of cancers from the prostate, kidney and bladder
|7:00 PM||Introduction and President's Remarks
John Cheville, MD, Mayo Clinic, Rochester, MN
|7:20 AM||Current Status of Active Surveillance as a Treatment Option for Genitourinary Cancers
Alan So, MD, FRCSC, University of British Columbia, Vancouver, BC, Canada
|8:00 PM||The Importance of Pathologic Evaluation in Active Surveillance of Prostate Cancer
Andrew J. Evans, MD, PhD, FRCPC, Toronto General Hospital, Toronto, ON, Canada
|8:30 PM||The Importance of Pathologic Evaluation in Active Surveillance of Small Renal Masses
Ying-Bei Chen, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
|9:00 PM||The Importance of Pathologic Evaluation in the Management of Non-Muscle Invasive Bladder Cancer
Donna Hansel, MD, PhD, University of California, San Diego, CA
Continuing Medical Education and Maintenance of Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and International Society of Urological Pathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.